Mercaptopurine and Lymph follicular hypertrophy - a phase IV clinical study of FDA data

Summary:

Lymph follicular hypertrophy is found among people who take Mercaptopurine, especially for people who are female, 20-29 old, have been taking the drug for 2 - 5 years.

The phase IV clinical study analyzes which people take Mercaptopurine and have Lymph follicular hypertrophy. It is created by eHealthMe based on reports of 19,865 people who have side effects when taking Mercaptopurine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 19, 2022

19,865 people reported to have side effects when taking Mercaptopurine.
Among them, 114 people (0.57%) have Lymph follicular hypertrophy.


What is Mercaptopurine?

Mercaptopurine has active ingredients of mercaptopurine. It is often used in crohn's disease. eHealthMe is studying from 17,983 Mercaptopurine users for its effectiveness, alternative drugs and more.

What is Lymph follicular hypertrophy?

Lymph follicular hypertrophy (an increase in the size of the lymph node follicles) is found to be associated with 2,416 drugs and 1,919 conditions by eHealthMe.

Number of Mercaptopurine and Lymph follicular hypertrophy reports submitted per year:

Could Mercaptopurine cause Lymph follicular hypertrophy?

Time on Mercaptopurine when people have Lymph follicular hypertrophy *:

Click here to view

Gender of people who have Lymph follicular hypertrophy when taking Mercaptopurine*:

Click here to view

Age of people who have Lymph follicular hypertrophy when taking Mercaptopurine *:

Click here to view

Common drugs people take besides Mercaptopurine *:

Click here to view

Common side effects people have besides Lymph follicular hypertrophy *:

Click here to view

Common conditions people have *:

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Mercaptopurine and have Lymph follicular hypertrophy?

Check whether Lymph follicular hypertrophy is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Lymph follicular hypertrophy and when was it recovered:

Expand to all the drugs that have ingredients of mercaptopurine:

Alternative drugs to, pros and cons of Mercaptopurine:

Common Mercaptopurine side effects:

Browse all side effects of Mercaptopurine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Lymph follicular hypertrophy treatments and more:

COVID vaccines that are related to Lymph follicular hypertrophy:

Common drugs associated with Lymph follicular hypertrophy:

All the drugs that are associated with Lymph follicular hypertrophy:

Common conditions associated with Lymph follicular hypertrophy:

All the conditions that are associated with Lymph follicular hypertrophy:

How the study uses the data?

The study uses data from the FDA. It is based on mercaptopurine (the active ingredients of Mercaptopurine) and Mercaptopurine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: